Novel drug first in Hong Kong to receive USFDA orphan drug designation
24 Oct 2019
A research team led by Professor Zhang Ge, Associate Director of HKBU's Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, and Professor Lyu Aiping, Director of HKBU's Institute of Integrated Bioinformedicine and Translational Science from the School of Chinese Medicine has successfully developed a novel aptamer, i.e. a single-stranded piece of DNA, for the treatment of osteogenesis imperfecta (OI) with the aid of artificial intelligence (AI) technology. It is the first time a drug in Hong Kong has been granted orphan drug designation by the US Food and Drug Administration (FDA).
The designation will bring a series of benefits to the subsequent research and development of the drug, such as tax credits when conducting qualified clinical trials. The research team expects that clinical trials can be conducted in three years' time, at the earliest.
Please click here for more details.